HIGHLIGHTS
- who: Anbukkarasi Muniyandi from the DepartmentIndiana University have published the research: PRMT5 is a therapeutic target in choroidal neovascularization, in the Journal: Scientific Reports Scientific Reports
- what: Based on the findings from this study, the authors provide evidence that PRMT5 methylates and activates NF-u03baB in endothelial cells. The authors provide experimental evidence that high expression of PRMT5, as observed in the murine L-CNV model and human nvAMD tissues, can impact the regulation of proangiogenic and proinflammatory NF-u03baB signaling; inhibiting PRMT5 with a potent small_molecule inhibitor, PR5-LL-CM01, offers potential therapeutic efficacy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.